Innovation Pharmaceuticals (Innovation Pharmaceuticals) Total Stockholders Equity : $1.16 Mil (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Total Stockholders Equity?

Innovation Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $1.16 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Innovation Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2023 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Innovation Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.20.

Innovation Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Innovation Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Total Stockholders Equity Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

-4.13

1.46

7.51

4.73

2.04

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															3.42	3.08	2.72	2.04	1.16

Innovation Pharmaceuticals (OTCPK:IPIX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Innovation Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1.162	-	0)	/	518.348
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Innovation Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.238	+	0)	/	1.162
	=	0.20

Innovation Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website

http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Executives

Arthur Peter Bertolino	officer: Pres. & Chief Medical Officer	C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness	officer: Vice President	100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin	director	C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor	director	17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter	director	7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich	director, 10 percent owner, officer: Chief Financial Officer	C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon	director, 10 percent owner, officer: President-Chief Scient.Officer	10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans	director, officer: Chief Executive Officer	17 IRVING PLACE, PELHAM NY 10803